Japan Medtech/Heathcare Sector "Implications of board appointments" Yoshihara

Research evidence excerpt

Japan Medtech/Heathcare Sector "Implications of board appointments" Yoshihara

Global Research

30 June 2026ab

Japan Medtech/Heathcare Sector Equities

JapanImplications of board appointments

Advanced Medical Devices

Tomoko Yoshihara

Covered companies with March fiscal year-ends held AGMs in June Analyst

Several companies changed management personnel and indicated plans to strengthen tomoko.yoshihara@ubs.com

initiatives aimed at improving profitability. The medical device sector can achieve +81-3-5208 6212

sustained growth in sales, given its high barriers to entry and stable patient volumes. We

believe companies that actively pursue price revisions and structural reforms can deliver

strong profit growth. In this context, NIPRO is the stock to watch. Enhancements to

governance that were announced in June 2026 should facilitate measures to improve

profitability. Olympus, Sysmex and H.U. Group Holdings also changed management

personnel, and we believe signs of profitability improvement could function as a share

price catalyst.

Nipro: The company replaced its president and five directors in May 2025 and

announced further enhancements to governance in June 2026 (link, Japanese only). It

restructured its board of directors, reducing the number of directors from 18 to nine and

strengthened oversight functions by appointing four independent outside directors

(link). At the same time, it established a new management committee to strengthen

execution capabilities. Some members of the management committee are externally

hired specialists who will strengthen initiatives aimed at improving profitability. We

believe stronger governance will drive further improvements in profitability.

Olympus: Following Bob White's appointment as CEO in June 2025, the company